Prostate Cancer - Results from #1080

ZNF397 Deficiency Triggers TET2-driven Lineage Plasticity and AR-Targeted Therapy Resistance in Prostate Cancer. April 11, 2024

CB307: A Dual Targeting Costimulatory Humabody VH Therapeutic for Treating PSMA-Positive Tumors. April 11, 2024

Expected impact of MRI-targeted biopsy interreader variability among uropathologists on ProScreen prostate cancer screening trial: a pre-trial validation study. April 11, 2024

Timing of Radiotherapy (RT) After Radical Prostatectomy (RP): Long-term outcomes in the RADICALS-RT trial [NCT00541047]. April 11, 2024

Predictive Models for Assessing Patients' Response to Treatment in Metastatic Prostate Cancer: A Systematic Review. April 11, 2024

Role of cytoreductive radical prostatectomy in men with oligometastatic prostate cancer on molecular imaging. April 10, 2024

Intra-fractional geometric and dose/volume metric variations of magnetic resonance imaging-guided stereotactic radiotherapy of prostate bed after radical prostatectomy. April 10, 2024

Exploring Unmet Needs in Prostate Cancer Care: A Cross-sectional Descriptive Study. April 10, 2024

Excess weight, weight gain, and prostate cancer risk and prognosis: the PROCA-life study. April 10, 2024

Current Systemic Therapy in Men with Metastatic Castration-Sensitive Prostate Cancer. April 10, 2024

Unmet Sexual Health Needs of Patients and Female Partners Following Diagnosis and Treatment for Prostate Cancer. April 10, 2024

Survivorship concerns among individuals diagnosed with metastatic cancer: Findings from the Cancer Experience Registry. April 10, 2024

Clinical Benefit and Regulatory Outcomes of Cancer Drugs Receiving Accelerated Approval April 9, 2024

FibroGen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer April 9, 2024

Physician Perspectives on the Nonclinical Factors That Contribute to Decision-Making for Advanced Prostate Cancer Care: A Qualitative Study April 9, 2024

Urinary extracellular vesicle-derived miR-126-3p predicts lymph node invasion in patients with high-risk prostate cancer. April 9, 2024

Disparities in the Delivery of Prostate Cancer Survivorship Care in the USA: A Claims-based Analysis of Urinary Adverse Events and Erectile Dysfunction Among Prostate Cancer Survivors. April 9, 2024

Validation of Prognostic and Predictive Models for Therapeutic Response in Patients Treated with [177Lu]Lu-PSMA-617 Versus Cabazitaxel for Metastatic Castration-resistant Prostate Cancer (TheraP): A Post Hoc Analysis from a Randomised, Open-label, Phase 2 April 9, 2024

How Can We Improve Patient-Clinician Communication for Men Diagnosed with Prostate Cancer? April 9, 2024

An Automated Deep Learning-Based Framework for Uptake Segmentation and Classification on PSMA PET/CT Imaging of Patients with Prostate Cancer. April 9, 2024

Page 55 of 1436